CureVac

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

CureVac Announces Update to the Management Team

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

CureVac Announces Voting Results of General Meeting

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

CureVac Announces Pricing of Upsized Public Offering of Common Shares

CureVac Announces Proposed Public Offering of Common Shares

CureVac Welcomes Myriam Mendila as New Chief Development Officer

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update